278 related articles for article (PubMed ID: 30575099)
1. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
Ma W; Ho DW; Sze KM; Tsui YM; Chan LK; Lee JM; Ng IO
Mol Carcinog; 2019 May; 58(5):643-653. PubMed ID: 30575099
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
Wang D; Li X; Li J; Lu Y; Zhao S; Tang X; Chen X; Li J; Zheng Y; Li S; Sun R; Yan M; Yu D; Cao G; Yang Y
Gut; 2019 Oct; 68(10):1846-1857. PubMed ID: 31154396
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3B and IL-6 form a positive feedback loop in hepatocellular carcinoma cells.
Li S; Bao X; Wang D; You L; Li X; Yang H; Bian J; Wang Y; Yang Y
Sci China Life Sci; 2017 Jun; 60(6):617-626. PubMed ID: 28646470
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop.
Lan T; Yuan K; Yan X; Xu L; Liao H; Hao X; Wang J; Liu H; Chen X; Xie K; Li J; Liao M; Huang J; Zeng Y; Wu H
Cancer Res; 2019 Jul; 79(13):3220-3234. PubMed ID: 31101763
[TBL] [Abstract][Full Text] [Related]
5. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
6. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D; Ruan Y; Zhou X
Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
[TBL] [Abstract][Full Text] [Related]
7. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
[TBL] [Abstract][Full Text] [Related]
8. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
9. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
10. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
Huang T; Guo YZ; Yue X; Zhang GP; Zhang Y; Kuang M; Peng BG; Li SQ
Carcinogenesis; 2020 Jul; 41(5):571-581. PubMed ID: 32649753
[TBL] [Abstract][Full Text] [Related]
11. Cripto-1 promotes tumor invasion and predicts poor outcomes in hepatocellular carcinoma.
Huang T; Guo YZ; Yue X; Zhang GP; Zhang Y; Kuang M; Peng BG; Li SQ
Carcinogenesis; 2020 Jul; 41(5):571-581. PubMed ID: 32648918
[TBL] [Abstract][Full Text] [Related]
12. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
[TBL] [Abstract][Full Text] [Related]
13. Cross talk between oxidative stress and hypoxia via thioredoxin and HIF-2α drives metastasis of hepatocellular carcinoma.
Cao MQ; You AB; Cui W; Zhang S; Guo ZG; Chen L; Zhu XD; Zhang W; Zhu XL; Guo H; Deng DJ; Sun HC; Zhang T
FASEB J; 2020 Apr; 34(4):5892-5905. PubMed ID: 32157720
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma.
Sun XF; Sun JP; Hou HT; Li K; Liu X; Ge QX
Tumour Biol; 2016 Nov; 37(11):15325-15332. PubMed ID: 27704356
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
16. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
17. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
18. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
[TBL] [Abstract][Full Text] [Related]
19. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
[TBL] [Abstract][Full Text] [Related]
20. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells.
Kazuma Y; Shirakawa K; Tashiro Y; Yamazaki H; Nomura R; Horisawa Y; Takeuchi S; Stanford E; Konishi Y; Matsui H; Matsumoto T; Tanabe F; Morishita R; Ito S; Takaori-Kondo A
Sci Rep; 2022 Feb; 12(1):2278. PubMed ID: 35145187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
